UK-based Oxford BioMedica has entered an alliance with clinical-stage biotechnology company Orchard Therapeutics to develop and supply lentiviral vectors used by the latter for the manufacture of ex-vivo gene therapy products.

The products will be manufactured in primary immune deficiency disorders and inherited metabolic disorders, including adenosine deaminase severe combined immunodeficiency (ADA-SCID), Mucopolysaccharidosis-IIIA (MPS-IIIA or Sanfilippo Syndrome type A) and undisclosed follow-on indications.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

People with ADA-SCID lack virtually all immune protection from bacteria, viruses, and fungi, while MPS III or Sanfilippo syndrome is a progressive disorder that mainly affects the brain and central nervous system.

Oxford BioMedica CEO John Dawson said: “The alliance combines Oxford BioMedica’s world-leading capabilities in lentiviral vector process development and bioprocessing expertise with Orchard’s expertise in the development and commercialisation of gene therapies for orphan diseases.

"This further demonstrates Oxford BioMedica’s position as a 'go-to' partner for companies and academic institutions working with lentiviral vector based products."

“This further demonstrates Oxford BioMedica’s position as a 'go-to' partner for companies and academic institutions working with lentiviral vector based products.”

See Also:

Orchard will be leading the global clinical development and commercialisation of collaboration programmes in Europe and the US, as well as in other regions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Under the agreement, Oxford will receive a 1.95% equity stake in Orchard and will also get royalties on future sales of products covered by the collaboration.

In addition, the Oxford University spin out will provide process development services and manufacture clinical and commercial GMP-grade lentiviral vectors for Orchard.

Through the process development arrangements including performance-related incentives, Oxford could receive a further 1.95% equity stake in Orchard.